DGDavid Gold

David Gold

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


David Gold has a total of 119 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    AnxEMU-VR: Randomized Controlled Trial Evaluating the Impact of Virtual Reality Exposure Therapy on Epilepsy-Specific Interictal Anxiety in People with Epilepsy (Preprint)

    by Samantha Evelyn Lewis-Fung, Vanessa Geitz, Danielle Tchao, Anjena Inthiran, Krisha Malik, Hannah Gabrielle Gray, David Gold, Esther Bui, Lora Appel

    BACKGROUND Anxiety is the most common psychiatric comorbidity among people with epilepsy, yet epilepsy-specific (ES) interictal anxiety remains underrecognized and undertreated, highlighting the need for accessible non-pharmacological approaches. Virtual reality exposure therapy (VR-ET) can deliver controlled exposure to seizure-related fears that are difficult to reproduce in vivo, but its effects and delivery requirements need evaluation in the context of seizure unpredictability and heterogeneous seizure experiences. The epilepsy monitoring unit (EMU) allows repeated engagement under medi OBJECTIVE This mixed-methods randomized controlled trial evaluated the preliminary effectiveness of VR-ET for ES-anxiety compared with neutral VR, together with feasibility, acceptability, usability, safety, tolerability, and scenario fidelity among people with epilepsy admitted to an EMU. METHODS Fourteen people with self-reported epilepsy- or seizure-related anxiety were randomized to VR-ET (n=7) or neutral VR (n=7). Participants completed self-administered 5-minute 360-degree video sessions twice daily for up to 10 days or until discharge. VR-ET participants progressed through personalized hierarchies of graded seizure-related exposure scenes selected at baseline using a diagnostic interview; control participants viewed nature-based scenes in a standardized order. Quantitative outcomes included anxiety, fear and situational avoidance, quality of life, simulator sickness, usability, and presence, and were summarized descriptively. Post-intervention and 1-month interviews were analyzed using framework analysis with inductive coding within predefined domains. Findings were integrated through joint interpretation and cross-case comparison. RESULTS Quantitative outcomes were heterogeneous and showed no clear between-group pattern. Adherence was high, with all VR-ET participants and 5 of 7 (71.4%) neutral VR participants meeting the predefined threshold. Five of 7 (71.4%) VR-ET participants described the intervention as helpful, and 4 of 7 (57.1%) reported experiences consistent with exposure-related learning, including increased insight, self-efficacy, preparedness, cognitive reappraisal, and habituation. Fear and anxiety changes were variable, and incomplete 1-month follow-up limited interpretation of longer-term outcomes. Scenarios were generally realistic and representative of epilepsy-related fears, but emotional engagement depended on personal relevance. Seizure simulations were identified as most impactful, and participants recommended greater intensity, variety, interactivity, and treatment duration. VR-ET participants more often expressed interest in continued use outside the EMU, whereas neutral VR participants primarily described short-term calming and distraction during admission with some reporting proactive use during periods of heightened anxiety. Across groups, usability was favorable, simulator sickness was minimal, and no serious adverse events were attributable to VR. Engagement was affected by EMU-related fatigue, seizure activity, environmental interruptions, and technical problems. CONCLUSIONS The VR interventions were feasible, acceptable, and safe in this sample. VR-ET showed no clear quantitative advantage over neutral VR, but qualitative findings were consistent with exposure-related learning. Neutral VR may provide low-intensity anxiety support during EMU admission. Future research should evaluate more personalized, varied, and interactive VR-ET and examine integration with therapist-supported care. CLINICALTRIAL ClinicalTrials.gov NCT06028945

  • Open Access

    Cognitive, Motor and Oculomotor Contributions to the Trail Making Test in Progressive Supranuclear Palsy

    by Indira Garcia‐Cordero, Mohsen Hadian, Juan Camilo Vargas‐Gonzalez, Marta Monteiro, David Gold, Abeer Khoja, Alonso Morales‐Rivero, Blas Couto, David Tang‐Wai, Susan Fox, et al.

    Background: Progressive supranuclear palsy (PSP) is a neurodegenerative disorder characterized by motor, oculomotor and cognitive impairments. Yet disentangling cognitive deficits from motor and oculomotor dysfunction remains a diagnostic and methodological challenge. Objectives: This study aims to evaluate how cognitive, motor, and oculomotor impairments contribute to performance in the Trail Making Test (TMT) in PSP patients. Methods: Eighty‐one patients with PSP‐Richardson's syndrome underwent the Toronto Cognitive Assessment, the Movement Disorder Society Unified Parkinson's Disease Rating Scale‐part III and the PSP rating scale. Structural equation modeling was used to examine associations between TMT performance, cognitive function, and motor/oculomotor measures derived from these assessments. Results: TMT performance was mainly driven by cognitive factors, particularly executive function, with no significant influence from motor or oculomotor deficits. Conclusions: These findings suggest that the TMT is a valuable tool for assessing cognitive impairment in PSP, reflecting fronto‐striatal (associative loop) dysfunction rather than motor or oculomotor impairments.

  • Open Access

    A pilot study of the feasibility and efficacy of an online group memory strategy training program for adults with epilepsy

    by Mary Lou Smith, Elizabeth N. Kerr, Mary Pat McAndrews, Rosalee Smith, Susan Hayman-Abello, Sahil Patel, David Gold


  • Open Access

    Sleep disturbances in older surgical patients with and without suspected cognitive impairment: A multicenter cohort study

    by Nina Butris, Ellene Yan, Yasmin Alhamdah, Paras Kapoor, Leif Erik Lovblom, Aparna Saripella, David Gold, Jean Wong, David F. Tang-Wai, Linda Mah, et al.

    Aims: Early detection and management of sleep disturbances can improve postoperative outcomes given the high prevalence of sleep disturbances and unrecognized cognitive impairment in older surgical patients. There is an association between sleep disturbances and cognitive impairment in the general population. However, the relationship in older surgical patients has not been systematically investigated. The objective of this study was to assess the prevalence and trajectory of preoperative and postoperative sleep disturbances in older surgical participants with and without suspected cognitive impairment (sCI). Methods: Two hundred and fifty-two participants aged ≥ 65 years undergoing non-cardiac surgery were recruited. The primary outcome was the prevalence and trajectory of sleep disturbances measured by the Pittsburgh Sleep Quality Index (PSQI) in participants with and without sCI preoperatively, 30, 90, and 180 days postoperatively. The main exposure, preoperative sCI, was operationalized as screening positive on one or more of the following cognitive screening tools: Centers for Disease Control and Prevention cognitive question (answered “yes”), Ascertain Dementia Eight-item Questionnaire (≥2), Telephone Montreal Cognitive Assessment (≤18), and Modified Telephone Interview for Cognitive Status (≤31). Sleep disturbances were defined as a PSQI score > 5. Mixed effects logistic regression models with random intercepts were used for the dichotomous outcome of sleep disturbances. Results: One hundred and eight participants (43%) screened positive for preoperative sCI. The prevalence of preoperative sleep disturbances was higher in participants with sCI versus without (63% vs 47%, P = 0.02). Postoperatively in both groups, the prevalence of sleep disturbances was lower at 30, 90, and 180 days, compared to the preoperative assessment and overall trajectories did not differ significantly. Female sex and depression were associated with poorer postoperative sleep, regardless of cognitive status. Conclusion: Sleep disturbances and suspected cognitive impairment are highly prevalent in surgical cohorts. Targeting conditions such as depression which affect sleep, may improve postoperative outcomes.


  • Open Access

    Translating the Interplay of Cognition and Physical Performance in COPD and Interstitial Lung Disease

    by Dmitry Rozenberg, W. Darlene Reid, Pat Camp, Jennifer L. Campos, Gail Dechman, Paul W. Davenport, Helga Egan, Jolene H. Fisher, Jordan A. Guenette, David Gold, et al.


  • Open Access

    Feasibility of a Home-Based Cognitive-Physical Exercise Program in Patients With Chronic Obstructive Pulmonary Disease: Protocol for a Feasibility and Pilot Randomized Controlled Trial

    by Dmitry Rozenberg, Josh Shore, Encarna Camacho Perez, Sahar Nourouzpour, Megha Ibrahim Masthan, Daniel Santa Mina, Jennifer L Campos, Ella Huszti, Robin Green, Mohammad Hashim Khan, et al.

    Background: Chronic obstructive pulmonary disease (COPD) is a progressive condition associated with physical and cognitive impairments contributing to difficulty in performing activities of daily living (ADLs) that require dual tasking (eg, walking and talking). Despite evidence showing that cognitive decline occurs among patients with COPD and may contribute to functional limitations and decreased health-related quality of life (HRQL), pulmonary rehabilitation continues to focus mainly on physical training (ie, aerobic and strength exercises). An integrated cognitive and physical training program compared to physical training alone may be more effective in increasing dual-tasking ability among people living with COPD, leading to greater improvements in performance of ADLs and HRQL. Objective: The aims of this study are to evaluate the feasibility of an 8-week randomized controlled trial of home-based, cognitive-physical training versus physical training for patients with moderate to severe COPD and derive preliminary estimates of cognitive-physical training intervention efficacy on measures of physical and cognitive function, dual task performance, ADLs, and HRQL. Methods: A total of 24 participants with moderate to severe COPD will be recruited and randomized into cognitive-physical training or physical training. All participants will be prescribed an individualized home physical exercise program comprising 5 days of moderate-intensity aerobic exercise (30-50 minutes/session) and 2 days of whole-body strength training per week. The cognitive-physical training group will also perform cognitive training for approximately 60 minutes, 5 days per week via the BrainHQ platform (Posit Science Corporation). Participants will meet once weekly with an exercise professional (via videoconference) who will provide support by reviewing the progression of their training and addressing any queries. Feasibility will be assessed through the recruitment rate, program adherence, satisfaction, attrition, and safety. The intervention efficacy regarding dual task performance, physical function, ADLs, and HRQL will be evaluated at baseline and at 4 and 8 weeks. Descriptive statistics will be used to summarize intervention feasibility. Paired 2-tailed t tests and 2-tailed t tests will be used to compare the changes in the outcome measures over the 8-week study period within and between the 2 randomized groups, respectively. Results: Enrollment started in January 2022. It is estimated that the enrollment period will be 24 months long, with data collection to be completed by December 2023. Conclusions: A supervised home-based cognitive-physical training program may be an accessible intervention to improve dual-tasking ability in people living with COPD. Evaluating the feasibility and effect estimates is a critical first step to inform future clinical trials evaluating this approach and its effects on physical and cognitive function, ADL performance, and HRQL. Trial Registration: ClinicalTrials.gov NCT05140226; https://clinicaltrials.gov/ct2/show/NCT05140226 International Registered Report Identifier (IRRID): DERR1-10.2196/48666


  • Open Access

    Feasibility of a Home-Based Cognitive-Physical Exercise Program in Patients With Chronic Obstructive Pulmonary Disease: Protocol for a Feasibility and Pilot Randomized Controlled Trial (Preprint)

    by Dmitry Rozenberg, Josh Shore, Encarna Camacho Perez, Sahar Nourouzpour, Megha Ibrahim Masthan, Daniel Santa Mina, Jennifer L Campos, Ella Huszti, Robin Green, Mohammad Hashim Khan, et al.

    BACKGROUND Chronic obstructive pulmonary disease (COPD) is a progressive condition associated with physical and cognitive impairments contributing to difficulty in performing activities of daily living (ADLs) that require dual tasking (eg, walking and talking). Despite evidence showing that cognitive decline occurs among patients with COPD and may contribute to functional limitations and decreased health-related quality of life (HRQL), pulmonary rehabilitation continues to focus mainly on physical training (ie, aerobic and strength exercises). An integrated cognitive and physical training program compared to physical training alone may be more effective in increasing dual-tasking ability among people living with COPD, leading to greater improvements in performance of ADLs and HRQL. OBJECTIVE The aims of this study are to evaluate the feasibility of an 8-week randomized controlled trial of home-based, cognitive-physical training versus physical training for patients with moderate to severe COPD and derive preliminary estimates of cognitive-physical training intervention efficacy on measures of physical and cognitive function, dual task performance, ADLs, and HRQL. METHODS A total of 24 participants with moderate to severe COPD will be recruited and randomized into cognitive-physical training or physical training. All participants will be prescribed an individualized home physical exercise program comprising 5 days of moderate-intensity aerobic exercise (30-50 minutes/session) and 2 days of whole-body strength training per week. The cognitive-physical training group will also perform cognitive training for approximately 60 minutes, 5 days per week via the BrainHQ platform (Posit Science Corporation). Participants will meet once weekly with an exercise professional (via videoconference) who will provide support by reviewing the progression of their training and addressing any queries. Feasibility will be assessed through the recruitment rate, program adherence, satisfaction, attrition, and safety. The intervention efficacy regarding dual task performance, physical function, ADLs, and HRQL will be evaluated at baseline and at 4 and 8 weeks. Descriptive statistics will be used to summarize intervention feasibility. Paired 2-tailed t tests and 2-tailed t tests will be used to compare the changes in the outcome measures over the 8-week study period within and between the 2 randomized groups, respectively. RESULTS Enrollment started in January 2022. It is estimated that the enrollment period will be 24 months long, with data collection to be completed by December 2023. CONCLUSIONS A supervised home-based cognitive-physical training program may be an accessible intervention to improve dual-tasking ability in people living with COPD. Evaluating the feasibility and effect estimates is a critical first step to inform future clinical trials evaluating this approach and its effects on physical and cognitive function, ADL performance, and HRQL. CLINICALTRIAL ClinicalTrials.gov NCT05140226; https://clinicaltrials.gov/ct2/show/NCT05140226 INTERNATIONAL REGISTERED REPORT DERR1-10.2196/48666

  • Open Access

    Sodium molybdate does not inhibit sulfate-reducing bacteria but increases shell growth in the Pacific oyster Magallana gigas

    by Roxanne M. W. Banker, Jacob Lipovac, John J. Stachowicz, David A. Gold

    Recent work on microbe-host interactions has revealed an important nexus between the environment, microbiome, and host fitness. Marine invertebrates that build carbonate skeletons are of particular interest in this regard because of predicted effects of ocean acidification on calcified organisms, and the potential of microbes to buffer these impacts. Here we investigate the role of sulfate-reducing bacteria, a group well known to affect carbonate chemistry, in Pacific oyster (Magallana gigas) shell formation. We reared oyster larvae to 51 days post fertilization and exposed organisms to control and sodium molybdate conditions, the latter of which is thought to inhibit bacterial sulfate reduction. Contrary to expectations, we found that sodium molybdate did not uniformly inhibit sulfate-reducing bacteria in oysters, and oysters exposed to molybdate grew larger shells over the experimental period. Additionally, we show that microbiome composition, host gene expression, and shell size were distinct between treatments earlier in ontogeny, but became more similar by the end of the experiment. Although additional testing is required to fully elucidate the mechanisms, our work provides preliminary evidence thatM.gigasis capable of regulating microbiome dysbiosis caused by environmental perturbations, which is reflected in shell development.


  • Open Access

    POS0086 ANALYSIS OF DISEASE ACTIVITY MEASURES IN THE CONTEXT OF A METHOTREXATE WITHDRAWAL STUDY AMONG PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH TOFACITINIB 11 MG ONCE DAILY + METHOTREXATE: POST HOC ANALYSIS OF DATA FROM ORAL SHIFT

    by R. Fleischmann, B. Haraoui, M. H. Buch, D. Gold, G. Sawyerr, H. Shi, A. Diehl, K. Lee

    Background: The Phase 3b/4 study ORAL Shift demonstrated sustained efficacy and safety of tofacitinib modified-release (MR) 11 mg once daily (QD) following methotrexate (MTX) withdrawal that was non-inferior to continued tofacitinib + MTX use (per DAS28-4[ESR]), in patients (pts) with rheumatoid arthritis (RA) who achieved CDAI-defined low disease activity (LDA) with tofacitinib + MTX at Week (W)24.1 Objectives: To assess the performance of alternative disease activity measures at W24 (randomisation) and W48 (study endpoint) in ORAL Shift. Methods: ORAL Shift (NCT02831855) enrolled pts aged ≥18 years with moderate to severe RA and an inadequate response to MTX. Pts received open-label tofacitinib MR 11 mg QD + MTX for 24 weeks. Achievement of CDAI LDA (≤10) at W24 was set as the criteria for entry to the 24-week double-blind MTX withdrawal phase, with pts randomised 1:1 to receive tofacitinib MR 11 mg QD + placebo (PBO) (ie blinded MTX withdrawal) or continue tofacitinib + MTX. In this post hoc analysis, efficacy analyses were performed in 8 subgroups defined by achievement of various disease activity criteria at W24: DAS28-4(ESR) remission (Results: Overall, 694 pts entered the open-label phase of ORAL Shift, and 530 were randomised and received treatment in the double-blind phase; 264 and 266 pts received tofacitinib + PBO and tofacitinib + MTX, respectively (Figure 1a). Considering those pts who were randomised and treated, the proportion of pts achieving each disease activity criterion at W24 varied, but was similar between treatments within each subgroup (Figure 1a). Among pts who met each disease activity criterion at W24, generally the majority of pts in both treatment groups also met the same criterion at W48 (Figure 1b). Numerically more pts receiving tofacitinib + MTX vs tofacitinib + PBO continued to meet the corresponding criterion at W48. Regardless of the disease activity criterion met at W24, differences between treatment groups in LS mean ΔDAS28-4(ESR) (Figure 1c) and ΔDAS28-4(CRP) (data not shown) from W24 to W48 favoured tofacitinib + MTX vs tofacitinib + PBO. Conclusion: This post hoc analysis of data from pts randomised and treated in ORAL Shift demonstrated that, regardless of the disease activity state criterion met at W24, generally a majority of pts receiving tofacitinib maintained achievement of the corresponding disease activity criterion at W48, with or without continued MTX. Differences between treatment groups in LS mean ΔDAS28-4(ESR) from W24 to W48, as defined by achievement of LDA or remission with a variety of disease activity measures, were less than a change of 1.2, which is considered to be the threshold for a minimal clinically important improvement.2 References: [1]Cohen et al. Lancet Rheumatol 2019; 1: E23-34. [2]Ward et al. Ann Rheum Dis 2015; 74: 1691-1696. Acknowledgements: Study sponsored by Pfizer Inc. Medical writing support was provided by Gemma Turner, CMC Connect, and funded by Pfizer Inc. Disclosure of Interests: Roy Fleischmann Speakers bureau: Pfizer Inc, Consultant of: AbbVie, Amgen, Bristol-Myers Squibb, Celltrion, Eli Lilly, GlaxoSmithKline, Janssen, Novartis, Pfizer Inc, Sanofi-Aventis, UCB, Grant/research support from: AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Celltrion, Eli Lilly, Genentech, GlaxoSmithKline, Janssen, Novartis, Pfizer Inc, Samumed, Sanofi-Aventis, UCB, VORSO, Boulos Haraoui Speakers bureau: Amgen, Pfizer Inc, UCB, Consultant of: AbbVie, Amgen, Eli Lilly, Merck, Pfizer Inc, UCB, Grant/research support from: AbbVie, Maya H Buch Speakers bureau: AbbVie, Consultant of: AbbVie, Eli Lilly, Gilead, MSD, Pfizer Inc, Roche, Sanofi, Grant/research support from: Pfizer Inc, Roche, UCB, David Gold Shareholder of: Pfizer Inc, Employee of: Pfizer Inc, Gosford Sawyerr Consultant of: Pfizer Inc, Employee of: Syneos Health Inc, Harry Shi Shareholder of: Pfizer Inc, Employee of: Pfizer Inc, Annette Diehl Shareholder of: Pfizer Inc, Employee of: Pfizer Inc, Kristen Lee Shareholder of: Pfizer Inc, Employee of: Pfizer Inc.